The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status

Background: The correlation between Ki-67 and epidermal growth factor receptor (EGFR)- or Kristen rat sarcoma viral oncogene homolog (KRAS)-mutant status in advanced or postoperative-recurrent non-small cell lung cancer (NSCLC) has fewer studies reported, and the prognostic role of Ki-67 with first-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weiguo Gu, Mingbin Hu, Linlin Xu, Yuanhui Ren, Jinhong Mei, Weijia Wang, Chunliang Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	non-small cell lung cancer tyrosine kinase inhibitor Ki-67 nomogram survival Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/700629ee2fee4d77b566202bf8f64cdd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:700629ee2fee4d77b566202bf8f64cdd
record_format	dspace
spelling	oai:doaj.org-article:700629ee2fee4d77b566202bf8f64cdd2021-11-05T09:49:20ZThe Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status2296-858X10.3389/fmed.2021.728575https://doaj.org/article/700629ee2fee4d77b566202bf8f64cdd2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.728575/fullhttps://doaj.org/toc/2296-858XBackground: The correlation between Ki-67 and epidermal growth factor receptor (EGFR)- or Kristen rat sarcoma viral oncogene homolog (KRAS)-mutant status in advanced or postoperative-recurrent non-small cell lung cancer (NSCLC) has fewer studies reported, and the prognostic role of Ki-67 with first-line EGFR-tyrosine kinase inhibitors (TKIs) or chemotherapy remains controversial.Methods: A total of 295 patients were tested for EGFR-mutant status in advanced or postoperative-recurrent NSCLC and received first-line EGFR-TKIs or chemotherapy for treatment. Ki-67 expression was retrospectively analyzed by immunohistochemistry. The Kaplan-Meier method was used to calculate survival rates. The multivariate Cox proportional hazards model was used to generate a nomogram. The established nomogram was validated using the calibration plots.Results: The expression levels of Ki-67 were divided into low (<60%, n = 186) and high (≥60%, n = 109) groups, based on the receiver operating characteristic curve. The expression levels of Ki-67 were found to be higher in patients with KRAS mutations when compared to KRAS wildtype, and EGFR wildtype was higher than EGFR mutations. The median overall survival (OS) of the low Ki-67 expression group was significantly longer than that of the high Ki-67 group, no matter in all NSCLC, EGFR mutations, EGFR wildtype, KRAS-mutant status, EGFR-TKIs, or chemotherapy of patients (P < 0.05). Subgroup analysis showed that the KRAS wildtype or EGFR mutations combine with low Ki-67 expression group had the longest median OS than KRAS mutations or EGFR wildtype combine with Ki-67 high expression group (P < 0.05). In the training cohort, the multivariate Cox analysis identified age, serum lactate dehydrogenase (LDH), serum Cyfra211, EGFR mutations, and Ki-67 as independent prognostic factors, and a nomogram was developed based on these covariates. The calibration curve for predicting the 12-, 24-, and 30-month OS showed an optimal agreement between the predicted and actual observed outcomes.Conclusions: The Ki-67 expression-based nomogram can well predict the efficacy of first-line therapy in NSCLC patients with EGFR- or KRAS-mutant status, high expression levels of Ki-67 correlated with a poor prognosis.Weiguo GuWeiguo GuMingbin HuMingbin HuLinlin XuLinlin XuYuanhui RenJinhong MeiJinhong MeiWeijia WangChunliang WangFrontiers Media S.A.articlenon-small cell lung cancertyrosine kinase inhibitorKi-67nomogramsurvivalMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer tyrosine kinase inhibitor Ki-67 nomogram survival Medicine (General) R5-920
spellingShingle	non-small cell lung cancer tyrosine kinase inhibitor Ki-67 nomogram survival Medicine (General) R5-920 Weiguo Gu Weiguo Gu Mingbin Hu Mingbin Hu Linlin Xu Linlin Xu Yuanhui Ren Jinhong Mei Jinhong Mei Weijia Wang Chunliang Wang The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
description	Background: The correlation between Ki-67 and epidermal growth factor receptor (EGFR)- or Kristen rat sarcoma viral oncogene homolog (KRAS)-mutant status in advanced or postoperative-recurrent non-small cell lung cancer (NSCLC) has fewer studies reported, and the prognostic role of Ki-67 with first-line EGFR-tyrosine kinase inhibitors (TKIs) or chemotherapy remains controversial.Methods: A total of 295 patients were tested for EGFR-mutant status in advanced or postoperative-recurrent NSCLC and received first-line EGFR-TKIs or chemotherapy for treatment. Ki-67 expression was retrospectively analyzed by immunohistochemistry. The Kaplan-Meier method was used to calculate survival rates. The multivariate Cox proportional hazards model was used to generate a nomogram. The established nomogram was validated using the calibration plots.Results: The expression levels of Ki-67 were divided into low (<60%, n = 186) and high (≥60%, n = 109) groups, based on the receiver operating characteristic curve. The expression levels of Ki-67 were found to be higher in patients with KRAS mutations when compared to KRAS wildtype, and EGFR wildtype was higher than EGFR mutations. The median overall survival (OS) of the low Ki-67 expression group was significantly longer than that of the high Ki-67 group, no matter in all NSCLC, EGFR mutations, EGFR wildtype, KRAS-mutant status, EGFR-TKIs, or chemotherapy of patients (P < 0.05). Subgroup analysis showed that the KRAS wildtype or EGFR mutations combine with low Ki-67 expression group had the longest median OS than KRAS mutations or EGFR wildtype combine with Ki-67 high expression group (P < 0.05). In the training cohort, the multivariate Cox analysis identified age, serum lactate dehydrogenase (LDH), serum Cyfra211, EGFR mutations, and Ki-67 as independent prognostic factors, and a nomogram was developed based on these covariates. The calibration curve for predicting the 12-, 24-, and 30-month OS showed an optimal agreement between the predicted and actual observed outcomes.Conclusions: The Ki-67 expression-based nomogram can well predict the efficacy of first-line therapy in NSCLC patients with EGFR- or KRAS-mutant status, high expression levels of Ki-67 correlated with a poor prognosis.
format	article
author	Weiguo Gu Weiguo Gu Mingbin Hu Mingbin Hu Linlin Xu Linlin Xu Yuanhui Ren Jinhong Mei Jinhong Mei Weijia Wang Chunliang Wang
author_facet	Weiguo Gu Weiguo Gu Mingbin Hu Mingbin Hu Linlin Xu Linlin Xu Yuanhui Ren Jinhong Mei Jinhong Mei Weijia Wang Chunliang Wang
author_sort	Weiguo Gu
title	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
title_short	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
title_full	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
title_fullStr	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
title_full_unstemmed	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
title_sort	ki-67 proliferation index-related nomogram to predict the response of first-line tyrosine kinase inhibitors or chemotherapy in non-small cell lung cancer patients with epidermal growth factor receptor-mutant status
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/700629ee2fee4d77b566202bf8f64cdd
work_keys_str_mv	AT weiguogu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT weiguogu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT mingbinhu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT mingbinhu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT linlinxu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT linlinxu theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT yuanhuiren theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT jinhongmei theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT jinhongmei theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT weijiawang theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT chunliangwang theki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT weiguogu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT weiguogu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT mingbinhu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT mingbinhu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT linlinxu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT linlinxu ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT yuanhuiren ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT jinhongmei ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT jinhongmei ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT weijiawang ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus AT chunliangwang ki67proliferationindexrelatednomogramtopredicttheresponseoffirstlinetyrosinekinaseinhibitorsorchemotherapyinnonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptormutantstatus
_version_	1718444295121272832

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status

Ejemplares similares